This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Grupo Ferrer Internacional, S.A.
Description: Lorediplon is an orally available non-benzodiazepine inhibitor of the gamma-aminobutyric acid A (GABA-A) receptor for the treatment of insomnia.
Ergomed and Ferrer and Ildong
Ergomed announced that it has entered into an agreement with Ferrer to support further clinical studies of Lorediplon in patients with insomnia. Ferrer also announced it is collaborating with Ildong Pharmaceuticals Co Ltd, Korea.
Ergomed Group is working with Ferrer as the clinical development organization to conduct the multicenter, multinational, randomized Phase IIa Lorediplon trial in insomnia. Under the terms of the agreement, Ergomed Group will assume a proportion of the clinical and regulatory costs of the Phase IIa trial in return for a share of future revenues received by Ferrer for Lorediplon in this indication. Under the terms of the Ildong agreement, Ferrer will be eligible to receive payments from the Co-operation and License Agreement covering countries within East Asia, including South Korea, China and Japan. Ildong will be responsible for the costs and activities related to development and regulatory approvals in their...See full deal structure in Biomedtracker
Partners: Ergomed PLC Ildong Pharmaceutical Co., Ltd.
Additional information available to subscribers only: